Two businessmen pushing giant puzzle pieces together as the sun sets behind them
Biotech

AbbVie inks $10.9B Apogee buyout to bag eczema prospect

The deal will give AbbVie control of a late-phase eczema drug candidate that could pose a threat to Eli Lilly, Regeneron and Sanofi.
Nick Paul Taylor Jun 22, 2026 7:59am
Photo of two train tracks merging into one

Serapha takes flight with $230M, gene-editing prospect from China

Jun 23, 2026 1:55pm
ipsen-heropng

Redefining PSC success through endpoint research.

Brought to you by Ipsen
for sale close down for sale sign business

Sangamo enters bankruptcy, reveals asset sales with 2 pharmas

Jun 23, 2026 10:57am
For biopharma manufacturing at speed and scale the future is flexible

For biopharma manufacturing at speed and scale, the future is flexible

Brought to you by Resilience
heart money

Merck KGaA pledges $50M to new biotech with eye to acquisition

Jun 23, 2026 10:16am
More News
Fierce Pharma

Obesity meds, China drive $2T in projected 2032 drug sales: report

Jun 23, 2026 9:00am

Fierce Biotech Fundraising Tracker '26: Nura, Memento & more

Jun 23, 2026 9:00am

Corxel touts ‘competitive’ ph. 2 results for oral GLP-1 asset

Jun 23, 2026 8:00am

Pfizer’s first new ADC from Seagen buy fails ph. 3 NSCLC trial

Jun 23, 2026 7:15am